Reported Earlier, HUTCHMED Begins Phase I Clinical Trial Of Menin Inhibitor HMPL-506 For Hematological Malignancies In China
Reported Earlier, HUTCHMED Begins Phase I Clinical Trial Of Menin Inhibitor HMPL-506 For Hematological Malignancies In China
据报道，和铂制药已在中国开始了用于血液恶性肿瘤的Menin抑制剂HMPL-506的I期临床试验。
This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in patients with hematological malignancies. The study is divided into two phases, a dose escalation phase and a dose expansion phase. The study is expected to enroll at least 60 patients. The lead principal investigators are Dr. Jianxiang Wang and Dr. Hui Wei of Chinese Academy of Medical Sciences Blood Diseases Hospital. Additional details may be found at clinicaltrials.gov, using identifier NCT06387082.
这是一项I期、多中心、开放标签的临床研究，旨在评估HMPL-506在血液恶性肿瘤患者中的安全性、药代动力学和疗效。该研究分为两个阶段，逐渐增加剂量阶段和剂量扩张阶段。该研究预计招募至少60名患者。首席主要研究员是中国医学科学院血液病医院的王建祥医生和魏辉医生。更多详细信息可在clinicaltrials.gov上查找，使用标识符NCT06387082。